GRAIL is combining what it calls high-intensity (ultrabroad and ultradeep) sequencing and population-based clinical trials to characterize circulating tumor DNA (ctDNA) in healthy individuals and cancer patients. The ultimate aim is to develop cancer diagnostics that can detect tumors early enough to cure the disease. See the full story at Genetic Engineering and Biotechnology News.
New Article in GEN
This is a core focus for all precision medicine oncology approaches, including ours. We believe that a multi-omic focus that goes beyond circulating tumor cells can have major advantages.